Advertisement


Irene M. Ghobrial, MD, on How COVID-19 is Changing the Conduct of Clinical Trials

COVID-19 and Cancer Care

Advertisement

Irene M. Ghobrial, MD, of Dana-Farber Cancer Institute, talks about PROMISE—her screening study for people at high-risk of developing precursor conditions of multiple myeloma­­—and how this and other trials have been altered in the wake of the pandemic, as well as what might be considered a silver lining to the crisis. Filmed March 30, 2020.



Related Videos

Hematologic Malignancies
COVID-19

Miguel-Angel Perales, MD, and Syed A. Abutalib, MD, on Bone Marrow Transplants During the COVID-19 Pandemic

Syed A. Abutalib, MD, of Cancer Treatment Centers of America, talks with Miguel-Angel Perales, MD, of Memorial Sloan Kettering Cancer Center, about the challenges and concerns related to transplants for patients with hematologic malignancies who are particularly vulnerable to infection with the coronavirus. Recorded July 13, 2020.

COVID-19
Hematologic Malignancies

Mehdi Hamadani, MD: In My Experience Question 4

How have the activities of the Center for International Blood and Marrow Transplant Research been affected by the COVID-19 pandemic?

Recorded April 21, 2020.

COVID-19
Global Cancer Care

Rafal Dziadziuszko, MD, PhD, on Using Telemedicine During the Pandemic: Experience in Poland

Rafal Dziadziuszko, MD, PhD, of the Medical University of Gdansk, talks about the adjustments to cancer care that he and his colleagues have made, how and when they employ telemedicine, and whether the technology could change the future for clinical practice. Filmed April 24, 2020.

Global Cancer Care
COVID-19

Giuseppe Curigliano, MD, PhD, on How COVID-19 Is Affecting Cancer Care: The View From Italy

Giuseppe Curigliano, MD, PhD, of the University of Milan, talks about how, in the face of the coronavirus pandemic, he and his fellow oncologists have altered the way they treat patients with cancer. Filmed March 24, 2020.

Hematologic Malignancies
COVID-19

William A. Wood, MD, MPH, on the New ASH Research Collaborative Data Hub COVID-19 Registry for Hematologic Malignancy

William A. Wood, MD, MPH, of the University of North Carolina at Chapel Hill, and Oversight Group Chair for the new COVID-19 registry, talks about why it was formed, how it can help patients and providers, and how it operates and could evolve in the future. Filmed April 3, 2020.

Advertisement

Advertisement




Advertisement